

**Debottlenecking mevalonate pathway for antimalarial drug precursor
amorphadiene biosynthesis in *Yarrowia lipolytica***

Monireh Marsafari, Peng Xu*

Department of Chemical, Biochemical and Environmental Engineering, University of
Maryland Baltimore County, Baltimore, MD 21250

* Corresponding author Tel: +1(410)-455-2474; fax: +1(410)-455-1049. E-mail
address: pengxu@umbc.edu (PX)

Table S1. Genes used in this paper.

Gene	Origin	Database and accession number	Optimization	References
<i>AaADS</i>	<i>Artemisia annua</i>	NCBI: AEQ63683.1	Yes	
<i>YlHMG1</i>	<i>Yarrowia lipolitica</i> Po1g	UniProtKB: Q6C704	Yes	(Huang et al., 2018)
<i>tYlHMG1</i>	<i>Yarrowia lipolitica</i> Po1g	UniProtKB: Q6C704	Yes	
<i>SpHMG1</i>	<i>Streptococcus pneumoniae</i>	UniProtKB - Q8DNS5	Yes	
<i>ScHMG1</i>	<i>Saccharomyces cerviciae</i>		Yes	(Basson, Thorsness, & Rine, 1986)
<i>ERG13</i>	<i>Yarrowia lipolitica</i> Po1g	GRYC ¹ : YALI0F30481g	Yes	(Martin, Pitera, Withers, Newman, & Keasling, 2003)
<i>ERG8</i>	<i>Yarrowia lipolitica</i> Po1g	GRYC: YALI0E06193g	Yes	(Martin et al., 2003)
<i>ERG10</i>	<i>Yarrowia lipolitica</i> Po1g	GRYC: YALI0B08536g	Yes	(Paddon et al., 2013)
<i>ERG12</i>	<i>Yarrowia lipolitica</i> Po1g	GRYC: YALI0B16038g	Yes	(Martin et al., 2003)
<i>MVD1</i>	<i>Yarrowia lipolitica</i> Po1g	GRYC: YALI0F05632g	Yes	(Martin et al., 2003)
<i>ERG20</i>	<i>Yarrowia lipolitica</i> Po1g	GRYC: YALI0E05753g	Yes	(Westfall et al., 2012)
<i>POT1</i>	<i>Yarrowia lipolitica</i> Po1g	GRYC: YALI0E18568g	Yes	
<i>PAT1</i>	<i>Yarrowia lipolitica</i> Po1g	GRYC: YALI0E11099g	Yes	

(1) GRYC refers to the genome resources for yeast chromosomes (<http://gryc.inra.fr/index.php?page=home>).

Table S2. Strains constructed in this paper.

Strain	Annotation	References
Po1g/ADS	Po1g containing pYLXP'-AaADS, used for the optimization of amorphadiene production	This work
Po1g/AYIH	Po1g containing pYLXP'-AaADS-YIHMG1, used for the optimization of amorphadiene production	This work
Po1g/AtYIH	Po1g containing pYLXP'-AaADS-tYIHMG1, used for the optimization of amorphadiene production	This work
Po1g/ASpH	Po1g containing pYLXP'-AaADS-SpHMG1, used for the optimization of amorphadiene production	This work
Po1g/AScH	Po1g containing pYLXP'-AaADS-tScHMG1, used for the optimization of amorphadiene production	This work
Po1g/AYlHERG8	Po1g containing pYLXP'- AaADS-YIHMG1-ERG8, used for the optimization of mevalonate pathway	This work
Po1g/AYlHERG12	Po1g containing pYLXP'- AaADS-YIHMG1-ERG12, used for the optimization of mevalonate pathway	This work
Po1g/AYlHMVD1	Po1g containing pYLXP'- AaADS-YIHMG1-MVD1, used for the optimization of mevalonate pathway	This work
Po1g/AYlHERG20	Po1g containing pYLXP'- AaADS-YIHMG1-ERG20, used for the optimization of mevalonate pathway	This work
Po1g/AYlH1 _{x2} E13E10E12	Po1g containing pYLXP'- AaADS-YIHMG1 _{x2} - ERG13-ERG10-ERG12 used for the optimization of amorphadiene production	This work
Po1g/AYlH1 _{x2} E13E10E12E8	Po1g containing pYLXP'- AaADS-YIHMG1 _{x2} - ERG13-ERG10-ERG12-ERG8 used for the optimization of amorphadiene production	This work
Po1g/A _{x2} tYIH	Po1g containing pYLXP'- AaADS _{x2} -tYIHMG1 used for the optimization of amorphadiene production	This work
Po1g/A _{x2} tYIHE12	Po1g containing pYLXP'- AaADS _{x2} -tYIHMG1-ERG12 used for the optimization of amorphadiene production	This work
Po1g/A _{x2} tYIHP	Po1g containing pYLXP'- AaADS _{x2} -tYIHMG1-YIPOT1 used for the optimization of amorphadiene production	This work
Po1g/A _{x2} tYIHE12P	Po1g containing pYLXP'- AaADS _{x2} -tYIHMG1-ERG12-YIPOT1 used for the optimization of amorphadiene production	This work
Po1g/A _{x2} tYIHP	Po1g containing pYLXP'- AaADS _{x2} -tYIHMG1-YIPOT1-YIPAT1 used for the optimization of amorphadiene	This work

production

Polg/A _{x2} tylHE12PP	Polg containing pYLXP'- AaADS _{x2} -tYlHMG1-ERG12- YlPOT1-YlPAT1 used for the optimization of amorphadiene production	This work
--------------------------------	--	-----------

Table S3. Primers used in this paper.


Primer	Sequence (5'-3')
YIHMG1 F	GCACCTTTGCAGTACTAACCGCAGCTACAAGCAGCTATTGGAAAGATTGTGG
YIHMG1 R	GGCCATGGAACTAGTCGGTACCTATGACCGTATGCAAATATCGAACCC
tYIHMG1 F	GCACCTTTGCAGTACTAACCGCAGCTACGAGAAGTTGTGCGAACCCAGTCTG
tYIHMG1 R	GCCATGGAACTAGTCGGTACCTATGACCGTATGCAAATATCGAACCC
SpHMG1 F	CCAGCACTTTGCAGTACTAACCGCAGACAGGGAAAACCGGCCATATAG
SpHMG1 R	ACAGGCCATGGAACTAGTCGGTACCTCATGTATTTCCAGAACCTGCTTC
tScHMG1 F	AGCACTTTGCAGTACTAACCGCAGGACCAGCTGTTAAAACAGAAGTA
tScHMG1 R	GACAGGCCATGGAACTAGTCGGTACCTTATGATTTATGCAGGTTACTGA
ERG13 F	CCGACCAGCACTTTGCAGTACTAACCGCAGTCGAACCCCAGAACGTTGG
ERG13 R	GGACAGGCCATGGAACTAGTCGGTACCGATGACGAACTAGAGCATGAAAG
ERG10 F	CCGACCAGCACTTTGCAGTACTAACCGCAGGAGCCGTCTACATTGTTCTAC
ERG10 R	GGACAGGCCATGGAACTAGTCGGTACCTAACACTCTCAACAATGATAGA
ERG8 F	CCGACCAGCACTTTGCAGTACTAACCGCAGACCACCTATCGGCTCCGGAAAG
ERG8 R	GGACAGGCCATGGAACTAGTCGGTACCTACTTGAACCCCTCTCGAGCCG
ERG12 F	CCGACCAGCACTTTGCAGTACTAACCGCAGGACTACATCATTCGGCGCCGAG
ERG12 R	GGGACAGGCCATGGAACTAGTCGGTACCTAATGGTCCAGGGACCGATG
MVD1 F	CCGACCAGCACTTTGCAGTACTAACCGCAGATCCACCAGGCCTCCACCACCGC
MVD1 R	GGACAGGCCATGGAACTAGTCGGTACCTACTTGCTGTTCTCAGAGAACCC
ERG20 F	CCAGCACTTTGCAGTACTAACCGCAGGCTTCAGAAAAAGAAATTAGGAGAG
ERG20 R	GGACAGGCCATGGAACTAGTCGGTACCTATTGCTTCTTGTAAAC
YIPOT1 F	CCGACCAGCACTTTGCAGTACTAACCGCAGGACCGACTAACAACCTCGCC
YIPOT1 R	GGACAGGCCATGGAACTAGTCGGTACTTACTCGGAACAAACCAGAGAACG
YIPAT1 F	GACCAGCACTTTGCAGTACTAACCGCAGCGACTCACTCTGCCCGACTAAC
YIPAT1 R	GGACAGGCCATGGAACTAGTCGGTACCTACTCGACAGAAGAGACCTTCTTG

Table S4. Plasmids used in this paper.


Plasmid	Annotation
pYLXP'	YaliBrick plasmid, used for pathway assemble
pYLXP'-AaADS	For the construction and optimization of amorphadiene production
pYLXP'-AaADS-YlHMG1	For the construction and optimization of amorphadiene production
pYLXP'-AaADS-tYlHMG1	For the construction and optimization of amorphadiene production
pYLXP'-AaADS-SpHMG1	For the construction and optimization of amorphadiene production
pYLXP'-AaADS-tScHMG1	For the construction and optimization of amorphadiene production
pYLXP'- AaADS-YlHMG1-ERG8	For the construction and optimization of mevalonate pathway
pYLXP'- AaADS-YlHMG1-ERG12	For the construction and optimization of mevalonate pathway
pYLXP'- AaADS-YlHMG1-MVD1	For the construction and optimization of mevalonate pathway
pYLXP'- AaADS-YlHMG1-ERG20	For the construction and optimization of mevalonate pathway
pYLXP'- AaADS-YlHMG1 _{x2} -ERG13-ERG10-ERG12	For the construction and optimization of mevalonate pathway and amorphadiene production
pYLXP'- AaADS-YlHMG1 _{x2} -ERG13-ERG10-ERG12-ERG8	For the construction and optimization of mevalonate pathway and amorphadiene production
pYLXP'- AaADS _{x2} -tylHMG1 ¹	For the construction and optimization of amorphadiene production
pYLXP'- AaADS _{x2} -tylHMG1-ERG12	For the construction and optimization of amorphadiene production
pYLXP'- AaADS _{x2} -tylHMG1-ylPOT1	For enhancing acetyl-CoA synthesis and improvement of amorphadiene production
pYLXP'- AaADS _{x2} -tylHMG1-ERG12-ylPOT1	For enhancing acetyl-CoA synthesis and improvement of amorphadiene production
pYLXP'- AaADS _{x2} -tylHMG1-ylPOT1-ylPAT1	For enhancing acetyl-CoA synthesis and improvement of amorphadiene production
pYLXP'- AaADS _{x2} -tylHMG1-	For enhancing acetyl-CoA synthesis and improvement

(1) The subscripts “_{x2}” refer to gene copy number in the plasmids.

Supplementary figures



Supplementary Figure S1. Effect of 3% oleic acid on amorphadiene production carried out for Po1g/AYIH. CSM-Leu media without Oleic acid used as a control condition



Supplementary Figure S2. Cerulenin optimization dosage carried out for Po1g/AYIH strain in leucine drop-out complete synthetic media (CSM-Leu).

References

- Basson, M. E., Thorsness, M., & Rine, J. (1986). *Saccharomyces cerevisiae* contains two functional genes encoding 3-hydroxy-3-methylglutaryl-coenzyme A reductase. *Proc Natl Acad Sci U S A*, 83(15), 5563-5567.
- Huang, Y. Y., Jian, X. X., Lv, Y. B., Nian, K. Q., Gao, Q., Chen, J., . . . Hua, Q. (2018). Enhanced squalene biosynthesis in *Yarrowia lipolytica* based on metabolically engineered acetyl-CoA metabolism. *J Biotechnol*, 281, 106-114. doi:10.1016/j.jbiotec.2018.07.001
- Markham, K. A., Palmer, C. M., Chwatko, M., Wagner, J. M., Murray, C., Vazquez, S., . . . Alper, H. S. (2018). Rewiring *Yarrowia lipolytica* toward triacetic acid lactone for materials generation. *Proceedings of the National Academy of Sciences of the United States of America*, 115(9), 2096-2101. doi:10.1073/pnas.1721203115
- Martin, V. J., Pitera, D. J., Withers, S. T., Newman, J. D., & Keasling, J. D. (2003). Engineering a mevalonate pathway in *Escherichia coli* for production of terpenoids. *Nat Biotechnol*, 21(7), 796-802. doi:10.1038/nbt833
- Paddon, C. J., Westfall, P. J., Pitera, D. J., Benjamin, K., Fisher, K., McPhee, D., . . . Newman, J. D. (2013). High-level semi-synthetic production of the potent antimalarial artemisinin. *Nature*, 496(7446), 528-532. doi:10.1038/nature12051
- Westfall, P. J., Pitera, D. J., Lenihan, J. R., Eng, D., Woolard, F. X., Regentin, R., . . . Paddon, C. J. (2012). Production of amorphadiene in yeast, and its conversion to dihydroartemisinic acid, precursor to the antimalarial agent artemisinin. *Proc Natl Acad Sci U S A*, 109(3), E111-118. doi:10.1073/pnas.1110740109
- Zha, W. J., Rubin-Pitel, S. B., Shao, Z. Y., & Zhao, H. M. (2009). Improving cellular malonyl-CoA level in *Escherichia coli* via metabolic engineering. *Metabolic Engineering*, 11(3), 192-198. doi:10.1016/j.ymben.2009.01.005